KLOW Blend Guide & Protocols

KLOW is different from every other protocol on this site in one important way: you're not dosing one peptide, you're dosing four at once, mixed in a single vial at a fixed ratio. Drawing more or less doesn't let you adjust one component without moving all four. Below is how people size a dose against that constraint, how it's cycled, and how it compares to GLOW, the three-peptide version KLOW is built from.

Because this is a fixed-ratio blend, the usual reconstitution calculator math works a little differently here. Our reconstitution calculator still handles the water-to-concentration math; what changes is that every draw contains a proportional slice of all four peptides, not just one.

What it is

KLOW combines GHK-Cu, BPC-157, TB-500, and KPV in one lyophilized vial, standardized across most vendors at a 5:1:1:1 ratio by weight: 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500, and 10 mg KPV, for an 80 mg total. It's sold as a research chemical, not an FDA-approved product, and none of the four components individually are approved for human use either. KLOW itself, as a combined formulation, has not been studied in any published trial; everything known about it comes from the individual research literature on each of its four ingredients.

What people use it for

KLOW sits at the intersection of skin and collagen support, general tissue and tendon repair, and gut or systemic inflammation, reflecting its four components' different research angles: GHK-Cu for collagen and dermal remodeling, BPC-157 and TB-500 for tissue and tendon repair, and KPV for inflammation modulation with a specific gut-health angle the three-peptide GLOW blend doesn't cover. People choosing KLOW over GLOW are usually adding an inflammation or gut-health interest on top of the shared repair-and-skin framing.

Formulations

KLOW ships as a lyophilized (freeze-dried) powder blend that needs reconstitution before use. The 80 mg vial at the 5:1:1:1 ratio (50 mg GHK-Cu / 10 mg BPC-157 / 10 mg TB-500 / 10 mg KPV) is the standard across vendors selling this blend; it isn't sold in other sizes or ratios the way single-compound peptides are. There's no oral or nasal commercial formulation, so subcutaneous injection of the reconstituted solution is the route people run, in a single shot that delivers all four peptides together.

Dosing protocols

There's no settled dose for KLOW as a combined product, and the usual "how many milligrams" question doesn't quite apply the way it does to a single peptide. What you're actually choosing is a total blend volume, and the 5:1:1:1 ratio fixes everything else from there.

See the KLOW blend research notes for the individual-component research before reading the dosing itself.

The ratio math

Every draw from a KLOW vial contains the same proportions: GHK-Cu is 62.5% of the total milligrams, and BPC-157, TB-500, and KPV are each 12.5%. At a common reconstitution of 4 mL bacteriostatic water for the 80 mg vial, that works out to a 20 mg/mL total concentration, and each 10-unit draw (0.1 mL) on an insulin syringe contains roughly 2 mg total: about 1.25 mg GHK-Cu and about 0.25 mg each of BPC-157, TB-500, and KPV. Reconstituting with a different amount of water changes the concentration but not the ratio, so use the reconstitution calculator for whatever volume you're actually working with rather than these example numbers.

Most commonly referenced pattern

A total blend dose sized so BPC-157 and TB-500 land around 250 to 500 mcg each, the range most commonly referenced for those two peptides on their own. At the 5:1:1:1 ratio, that means a total draw of roughly 2 to 4 mg, which correspondingly delivers about 1.25 to 2.5 mg of GHK-Cu and about 250 to 500 mcg of KPV. This is the reasoning most sources use to size a KLOW dose, working backward from the two repair peptides' own established ranges rather than from any figure specific to the blend.

Because the ratio is fixed, there's no way to raise BPC-157 or TB-500 without proportionally raising GHK-Cu and KPV too. Some people who want more of the repair peptides specifically add a small amount of standalone BPC-157 or TB-500 on top of their KLOW dose rather than increasing the whole blend; see Stacking below.

How often that dose actually gets drawn matters too, since KLOW only ships in the one 80 mg size with no smaller vial to switch to. See Storage and handling below for what that means for the reconstituted vial's shelf life.

Cycling guidelines

Six to eight weeks on, followed by two to four weeks off, is the pattern most commonly described for KLOW, closer to the repair-focused cycling seen with BPC-157 and TB-500 individually than to GHK-Cu's own more continuous convention. We couldn't find a source for where that specific window came from for the blend as a whole.

Signs a cycle is commonly stopped early:

• Persistent injection-site reaction beyond mild, brief redness
• Any new symptom you can't otherwise explain, which is harder to attribute to one component when four peptides are in the same shot
• Digestive changes that don't resolve, given KPV's gut-focused mechanism

Stacking

KLOW is already a four-peptide stack, so "stacking" here mostly means what people add on top of it, not a separate compound run alongside it.

Adding standalone BPC-157 or TB-500: since the blend's fixed ratio caps how much of either repair peptide you get without also raising GHK-Cu and KPV, some people add a small standalone dose of BPC-157 or TB-500 to weight the repair angle more heavily. This is two separate products run together, not a documented combination protocol.

Redundant additions: adding standalone GHK-Cu on top of KLOW is generally considered unnecessary, since GHK-Cu already makes up the majority of the blend by weight.

Longevity-adjacent stacks: some people run KLOW alongside Epithalon or similar longevity-framed peptides during the same general period, on the reasoning that skin and tissue repair pair naturally with a broader anti-aging interest. That's rationale plus a loosely matched schedule, not a studied combination.

Combinations to approach carefully: because KLOW already delivers four active peptides in one injection, adding more compounds on top makes it harder to identify which ingredient is behind any effect, or any side effect, you notice. That's worth weighing before adding a fifth or sixth peptide into the mix.

Expected results timeline

Early days: mostly an adjustment period for the injection routine itself. Anything noticed in the first several days is more likely the routine or placebo than the blend doing its work.

During a cycle: this is where most self-reported changes cluster, commonly skin texture and general recovery from minor strains, entirely self-reported and not measured against a control group.

Cumulative, across repeated cycles: any collagen, tissue-repair, or inflammation-marker change would only show up here, and it's the piece with the least real-world evidence behind it, since the underlying data is individual-component preclinical and early clinical work, not a study of the combined blend.

What to expect realistically: four peptides with individually interesting research profiles, combined into a product that has never itself been studied. Skin and general recovery changes are the most commonly described signal. A measurable biomarker change without lab testing isn't a reasonable expectation.

Administration technique

1. The lyophilized powder blend is reconstituted with bacteriostatic water, at a concentration set by the reconstitution calculator for your target total dose.
2. The solution is swirled gently to dissolve rather than shaken, since agitation can degrade the peptides.
3. The calculated volume, containing all four components at once, is drawn into a single insulin syringe.
4. A subcutaneous site is chosen, commonly the abdomen, with sites rotated across the week.
5. The skin is pinched and the injection given at roughly a 45-degree angle, held for a few seconds before withdrawal.
6. Each injection is commonly logged by date, total volume drawn, and site, since a single log entry captures all four components at once.

Side effects and safety

Common: mild redness or irritation at the injection site.

Less common: mild digestive changes reported anecdotally, plausibly tied to KPV's gut-focused mechanism, though not measured in any controlled way.

What we don't know: KLOW as a combined product has no human safety data of its own. Its four components have very different individual evidence depth, GHK-Cu has real human dermatology data, BPC-157 and TB-500 have preclinical animal data plus early human trials for their parent compounds, and KPV's human data is essentially absent outside preclinical models. Because all four arrive in a single injection, an adverse reaction can't be cleanly attributed to one ingredient.

Contraindications: anyone with active cancer or a personal history of cancer should be cautious with GHK-Cu given its role in cell proliferation signaling, and the same caution that applies to BPC-157 and TB-500 individually carries over here. Pregnancy, breastfeeding, and use in minors all have no data behind them and should be avoided.

Drug interactions: none have been formally characterized for the blend or for KPV specifically. That's an absence of data, not evidence of safety.

KLOW vs. GLOW

If you're weighing KLOW against something else, GLOW is the obvious comparison, since KLOW is GLOW with one peptide added.

Choose KLOW if: a gut-health or broader systemic inflammation interest sits alongside your skin and repair goals.

Choose GLOW if: skin and tissue repair are the whole interest, and you'd rather not add a fourth peptide with a thinner individual evidence base.

See the GLOW blend research notes for pricing and vendor info.

Storage and handling

Lyophilized powder: store protected from light; refrigerate for shorter holds or freeze for longer-term storage. Commonly described as stable 12 to 24 months when stored correctly, though lot-specific stability should come from the vendor's certificate of analysis.

Reconstituted solution: refrigerate, and plan to use it within about 4 to 6 weeks, a somewhat longer window than some single peptides, though vendor-specific guidance should take priority.

Matching the vial to that window: KLOW is sold as a single 80 mg vial at the fixed 5:1:1:1 ratio, and no smaller size is available from vendors carrying it. That matters because how often the vial actually gets drawn from determines whether it gets used up before the window above closes. A total blend draw in the 2 to 4 mg range described in Dosing protocols works out to roughly 20 to 40 doses per vial; fitting that many doses into 4 to 6 weeks means dosing close to daily to every other day. A lighter schedule, three times a week or less, stretches those same 20 doses toward 7 weeks, past the reconstituted solution's shelf life. With no smaller vial to switch to instead, the realistic options are reconstituting only part of the powder at a time so the rest stays dry and stable until it's needed, or planning on some reconstituted solution going unused if dosing less often than every other day.

Signs of degradation:

• Cloudiness or visible particles in a solution that was previously clear
• Discoloration of the powder or reconstituted liquid
• A cycle that produces none of the previously noticed subjective effects, though this is a soft signal at best

FAQ

Can I adjust just one peptide in KLOW? Not from the vial itself; the 5:1:1:1 ratio is fixed. Some people add standalone BPC-157 or TB-500 on top to weight the repair angle more heavily; see Stacking above.

How much of each peptide am I getting per injection? It depends on your reconstitution volume and draw size, but the proportions stay fixed: 62.5% GHK-Cu, 12.5% each BPC-157, TB-500, and KPV. Use the reconstitution calculator for your specific numbers.

How is KLOW different from GLOW? KLOW adds KPV, bringing a gut and systemic inflammation angle that GLOW's three peptides don't cover on their own.

How long is a typical cycle? Most commonly 6 to 8 weeks, followed by a 2 to 4 week break, though the specific window has no traceable source for the blend as a whole.

Is there human data on KLOW itself? No. Everything known comes from research on the four individual components; the combined blend has never been studied as a product.

Which component is responsible if I notice a side effect? There's no reliable way to know from a single combined injection. That's a real tradeoff of using a premade blend instead of separate single-peptide vials.

How is it stored? Protected from light as a powder, refrigerated and used within 4 to 6 weeks once reconstituted.

Can I buy the four peptides separately instead? Yes, and doing so lets you set each dose independently rather than accepting the blend's fixed ratio; it's a tradeoff between the convenience of one vial and the flexibility of four.

Bottom line

Key dosing takeaways:

• The 5:1:1:1 ratio is fixed, so sizing a dose means choosing a total blend volume, not a single peptide's amount
• Working backward from BPC-157 and TB-500's own typical 250 to 500 mcg range is the most common way people size a KLOW dose, which lands GHK-Cu around 1.25 to 2.5 mg and KPV around 250 to 500 mcg
• None of this traces to a study of the combined blend; it's individual-component convention applied to a fixed ratio

Best practices:

• Use the reconstitution calculator for your actual water volume rather than the example numbers above, since the ratio holds but the concentration doesn't
• Logging total volume drawn, not four separate peptide amounts, is enough since the ratio is fixed
• A rest period between cycles is standard across every version of this protocol, mirroring BPC-157 and TB-500's own cycling convention

Works best for people who:

• Want skin and repair support plus a gut or systemic inflammation angle in one product
• Are comfortable with a fixed ratio rather than independently dosing each of the four components
• Are fine with real uncertainty about the combined blend specifically, on top of the uncertainty that already applies to each ingredient on its own